Home » Stocks » Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc. (PRTK)

Stock Price: $4.81 USD 0.06 (1.26%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed
After-hours: $4.70 -0.11 (-2.29%) Oct 27, 6:26 PM

Stock Price Chart

Key Info

Market Cap 218.31M
Revenue (ttm) 30.15M
Net Income (ttm) -110.66M
Shares Out 45.39M
EPS (ttm) -2.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 27, 2020
Last Price $4.81
Previous Close $4.75
Change ($) 0.06
Change (%) 1.26%
Day's Open 4.76
Day's Range 4.74 - 4.91
Day's Volume 389,185
52-Week Range 2.50 - 6.72

More Stats

Market Cap 218.31M
Enterprise Value 293.02M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 45.39M
Float 39.45M
EPS (basic) -3.00
EPS (diluted) -2.92
FCF / Share -2.63
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.78M
Short Ratio 6.33
Short % of Float 9.59%
Beta 1.32
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 7.24
PB Ratio n/a
Revenue 30.15M
Operating Income -94.21M
Net Income -110.66M
Free Cash Flow -114.87M
Net Cash -74.71M
Net Cash / Share -1.65
Gross Margin -87.89%
Operating Margin -312.52%
Profit Margin -367.10%
FCF Margin -381.03%
ROA -23.38%
ROE -1,459.30%
ROIC -25.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(305.41% upside)
Current: $4.81
Target: 19.50
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-3.35%35.68%43403.45%--808.37%-95.66%-44.01%57.55%-
Gross Profit13.0617.1212.620.03-4.340.489.6019.6912.50
Operating Income-116-104-85.16-110-73.61-7.80-7.54-11.86-3.76-9.22
Net Income-129-112-89.07-112-70.86-17.84-4.65-12.02-3.88-9.30
Shares Outstanding32.7931.5126.8320.2516.502.530.061.421.131.12
Earnings Per Share-3.93-3.57-3.32-5.51-4.29-7.82-185.13-8.40-3.48-8.28
Operating Cash Flow-134-81.18-78.57-94.10-54.68-18.53-6.36-15.21-5.71-19.55
Capital Expenditures-0.24-0.06-1.12-0.69-0.86---0.04-0.06-0.07
Free Cash Flow-134-81.24-79.69-94.79-55.54-18.53-6.36-15.25-5.77-19.61
Cash & Equivalents21625115212913498.801.2185.4862.5668.17
Total Debt26322959.1938.9719.57-1.35---
Net Cash / Debt-47.1221.6692.7089.8811498.80-0.1485.4862.5668.17
Book Value-39.6547.5882.4871.5910195.22-11495.3965.7563.81
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Paratek Pharmaceuticals, Inc.
Country United States
Employees 101
CEO Evan Loh

Stock Information

Ticker Symbol PRTK
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PRTK


Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Company and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.